

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

26 April 2013

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(12 pages by email)

Dear Madam

CEO PRESENTATION AT THE 2013 BIO INTERNATIONAL CONVENTION

26 April 2013, Sydney, Australia – Biotron Limited's (ASX:BIT) Managing Director, Dr Michelle Miller, presented the attached update of the Company's activities this week to an international audience at the [2013 BIO International Convention](#). Hosted by the Biotechnology Industry Organization [Biotechnology Industry Organization](#) (BIO), this year's global event for biotechnology has been underway this week at the McCormick Place in Chicago, Illinois, USA.

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities. A key feature of BIO is the Business Forum which provides a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities in one-on-one meetings and corporate presentations.


The Company recently announced positive headline data from its Phase 1b/2a trial of BIT225 in HIV-infected subjects. BIT225 targets HIV in long-lived virus reservoir cells, and may be useful in future elimination strategies.

In addition, in another Phase 1b/2a trial, 100% of patients infected with Hepatitis C virus, who received BIT225 (400 mg) in combination with interferon and ribavirin, had undetectable HCV after 48 weeks.

A Phase 2 trial of BIT225 in HIV/HCV co-infected patients is currently in progress.

For further information please contact Dr Michelle Miller, Managing Director, on 61 (0)412 313 329.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn7194

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.

BIOTRON LIMITED (ASX:BIT)

Clinical Stage Antiviral Drug Development Company

Michelle Miller

CEO & Managing Director

+61 (0) 412 313 329

mmiller@biotron.com.au

Biotron



Forward Looking Statements






This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Biotron Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron’s current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

Biotron Limited Overview

- Clinical stage antiviral drug development company
 - Focus on developing novel small molecule drugs
 - Clinical programs for Hepatitis C virus (HCV) and HIV
 - Earlier stage programs include Dengue and others
 - Headquartered in Sydney, Australia
- ***Key recent highlights***
 - ***Mar 2013 – Announced positive preliminary headline results from Phase 2a HIV reservoir trial***
 - ***Nov 2012 – Commenced Phase 2 HIV/HCV co-infection trial***
 - ***Nov 2012 – Announced positive 48-week follow-up data from Phase 2a HCV trial***



Biotron - Advanced Pipeline of Clinical Programs

INDICATION	VIRAL TARGET	DISCOVERY	PRE-CLINICAL	PHASE 1a	PHASE 1b	PHASE 2a	PHASE 2b	STATUS
HEP C	p7							Ph 2a complete; Ph 2b (3 mth dosing) scheduled for 4Q13
HIV	Vpu							Ph 1b/2a complete
Hep C/HIV	Vpu/p7							Ph 2 In progress
Dengue	M							
Next generation for HCV	p7							Ready for IND- enabling (formal preclinical) studies

Biotron



BIT225 and Hepatitis C

- New investigational oral drug for treating HCV infection
- First in class; targets p7 protein – essential for virus assembly and release
- Preclinical studies – synergism with IFN/RBV and polymerase inhibitors
- Three completed trials:
 - **Phase Ia** –Single dose, dose-escalating safety study in healthy volunteers (n=48)
 - **Phase Ib** - 7-day multiple dose study in patients with HCV (n=18)
 - **Phase 2a** – 28-day multiple dose study in patients with HCV (gen 1) in combination with IFN/RBV (n=24)
 - 12-week data presented at HepDART, Dec 2011
 - 48-week headline data presented at AASLD, Nov 2012
 - Additional PK and resistance data to be presented at EASL, April 2013




BIT225 HCV Phase 2 Clinical Information

Treatment	Median log reduction at 35 days	% Complete EVR (<50IU/ml at 12 weeks)	% ETVR (<50IU/ml at 48 weeks)
400 mg BIT225 + IFN/RBV	-4.957	86	100
200 mg BIT225 + IFN/RBV	-4.351	88	88
Placebo + IFN/RBV	-3.649	63	75


- Clear demonstration that this first in class, direct-acting antiviral drug has good antiviral activity in treatment-naïve genotype 1 patients
- Generally well tolerated at the doses selected in trial
- Confirmed preclinical efficacy studies that demonstrated synergism with IFN and RBV

BIT225 and HIV

- BIT225 also has potent anti-HIV activity
 - Unique mode of action targets HIV “hiding” in long-lived reservoir cells
 - Reservoirs are last of the holy grail in HIV
 - No existing drugs target this source of HIV in the body
- Phase 2a trial of BIT225 in HIV-infected subjects recently completed
 - 10 days dosing (treatment-naïve, high viral load, CD4 >350)



+BIT225



Control

Headline results show that BIT225 can significantly reduce HIV levels in these reservoir cells in HIV-infected subjects

Results support a potential role for BIT225 in eradication strategies

BIT225 - HIV / HCV Co-Infected Population

- 25 – 40% of HIV-infected people in the USA are also HCV-infected
 - Significantly worse prognosis than mono-infected patients
 - US and European regulatory agencies have stated the need for new treatment strategies for this difficult-to-treat population
- Phase 2 HIV/HCV trial in progress
 - Treatment-naïve to HCV treatment with RBV and/or IFN; virologically suppressed on ART
 - Genotypes 1 and 3
 - 28 day dosing in combination with IFN/RBV
 - Recruitment and clinical phase anticipated to be complete by mid-2013

BIT225 is uniquely placed due to dual anti-HIV and anti-HCV activity



Biotron Programs Summary

- Documented need for new antiviral drugs
 - Licensing space is very active
- BIT225 has shown good clinical efficacy against both HCV and HIV
 - **Potential to be used with new (DAA) or existing classes of HCV drugs**
 - Phase 2b, 3 month study in combination with IFN/RBV anticipated to commence 4Q13
 - **Potential for use in HIV/HCV co-infected population**
 - Major unmet medical need
 - No other drugs target both HIV and HCV
 - **Potential role for BIT225 in elimination/cure strategies for HIV**
- Currently progressing development of next-generation inhibitors
- Promising early stage drug discovery program for Dengue
- Seeking partner(s) for further development of BIT225 and development of next generation of inhibitors

Key Financials and Facts

KEY FINANCIALS

ASX Code	BIT
Recent Share Price (23 April 2013)	A\$0.11
52 Week High	A\$0.185
52 Week Low	A\$0.08
Shares on Issue	228 million
Market Capitalization	A\$25 m
Net Cash (31 Dec '12)	A\$6.3 m

BOARD AND MANAGEMENT

Mr Michael Hoy	Chairman
Dr Michelle Miller	CEO & Managing Director
Dr Denis Wade	Non-Executive Director
Dr Susan Pond	Non-Executive Director
Mr Robert Thomas	Non-Executive Director
Mr Bruce Hundertmark	Non-Executive Director
Mr Peter Nightingale	CFO & Company Secretary

BIT - Daily Line Chart [Close]



Biotron